0.005% Latanoprost Gel for Nonsegmental Vitiligo
ConditionVitiligo - Macular Depigmentation
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age10-17
SponsorUniversitas Padjadjaran
About this trial
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation. PGF2α has been shown to stimulate the growth of melanocyte dendrites, increasing dendricity even at low doses, as well as enhancing tyrosinase activity and quantity, thereby promoting repigmentation. Studies on the use of 0.005% latanoprost gel in both children and adults with vitiligo have demonstrated effective repigmentation without reported side effects.
Eligibility criteria
Qualifiers
Patients with non-segmental vitiligo.
Patients with stable vitiligo for at least 6 months based on the Vitiligo Disease Activity (VIDA) score.
Aged 10-17 years.
Affected area <10%.
Disqualifiers
Use of topical therapy (corticosteroids, calcineurin inhibitors, psoralen, and antioxidants) for at least 2 weeks before the study, systemic therapy (corticosteroids, antioxidants, and vitamin D) for at least 4 weeks before the study, and phototherapy for at least 4 weeks before the study.
Presence of other active autoimmune diseases such as type 1 diabetes mellitus, thyroid disease, alopecia areata, rheumatoid arthritis, or Addison's disease, based on medical history and physical examination.
History of or current skin cancer, photosensitivity, or undergoing radiotherapy.
Allergy or contraindication to topical corticosteroids or latanoprost.
Trial design
Treatments tested in this trial
- 0.005% latanoprost gel
- 0.1% mometasone furoate cream
Treatment groups
10 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov